Multifunctional applications and research advances of low-molecular-weight heparin

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Low-molecular-weight heparin (LMWH) is a class of anticoagulant drugs derived from the controlled depolymerization of heparin. LMWH possesses a lower molecular weight and a shorter glycan chain length than unfractionated heparin (UFH), resulting in higher bioavailability, a more predictable pharmacokinetic profile, and consequently, a more convenient administration route. These characteristics make LMWH a primary choice for thromboprophylaxis of deep vein thrombosis. LMWH is clinically indicated for the prevention and treatment of venous thromboembolic diseases. Its role in obstetric complications, inflammation modulation, and antitumor therapy is also increasingly being recognized. The objective of this review was to systematically summarize the progress of LMWH research and to thoroughly explore its mechanisms of action and clinical indications. By analyzing the advantages and disadvantages of LMWH, evaluating its safety and adverse reactions, discussing the challenges in its clinical application, and proposing future research directions, in this review, we aim to promote the application and development of LMWH in a broader range of fields.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.